South Korea-based Samsung Biologics has signed a long term contract with United States-based Ichnos Sciences for manufacturing drug substance for ISB 830, an anti-OX40 monoclonal antibody in development as a potential treatment for moderate-to-severe atopic dermatitis, it was reported yesterday.
The company says that the product is based on an entirely new mechanism of action and has the potential to treat a range of autoimmune diseases beyond atopic dermatitis. Samsung Biologics and Ichnos (formerly known as Glenmark Pharmaceuticals SA) first entered into a Master Services Agreement in 2017 for Samsung Biologics to provide Ichnos with process optimisation and manufacturing services.
The company has started enrolment in a large randomised placebo-controlled Phase 2b study in atopic dermatitis and results are likely to be revealed in the first half of 2020.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval